Tiffany Tyson
Family · Raleigh, NCNPI 1497071153
Payments from drug & device makers
Across 415 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$934
- Otsuka America Pharmaceutical, Inc.$840
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$767
- plus $4K from 13 others
What the payments were for
- Speaking & faculty fees$2,48121%
- Travel & lodging$40%
- Food & beverage$9,05177%
- Education$1691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $2,726 |
| Alkermes, Inc. | 62 | $1,377 |
| Neurocrine Biosciences, Inc. | 42 | $1,024 |
| Johnson & Johnson | 48 | $934 |
| Otsuka America Pharmaceutical, Inc. | 39 | $840 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $767 |
| Teva Pharmaceuticals USA, Inc. | 37 | $752 |
| AbbVie | 38 | $665 |
| E.r. Squibb & Sons, L.L.C. | 19 | $558 |
| Sunovion Pharmaceuticals Inc. | 29 | $429 |
| Axsome Therapeutics, Inc. | 12 | $359 |
| Corium, LLC | 11 | $280 |
| Vanda Pharmaceuticals Inc. | 15 | $271 |
| Supernus Pharmaceuticals, Inc. | 2 | $259 |
| Idorsia Pharmaceuticals US Inc | 5 | $202 |
| Lundbeck LLC | 6 | $131 |
| Acadia Pharmaceuticals Inc | 1 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Almatica Pharma LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,705 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 121 | $323,774 |
| AustedoDeutetrabenazine | 36 | $164,287 |
| IngrezzaValbenazine Tosylate | 18 | $162,449 |
| VraylarCariprazine Hcl | 96 | $145,150 |
| Abilify MaintenaAripiprazole | 50 | $122,132 |
| RexultiBrexpiprazole | 68 | $97,426 |
| Lurasidone Hcl | 159 | $29,892 |
| AristadaAripiprazole Lauroxil | 14 | $22,682 |
| LatudaLurasidone Hcl | 12 | $17,454 |
| Aripiprazole | 218 | $6,753 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,435 |
| Paliperidone ErPaliperidone | 53 | $5,628 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,497 |
| InvegaPaliperidone | 13 | $4,488 |
| Divalproex Sodium ErDivalproex Sodium | 128 | $4,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega | $934 | $328,262134 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $840 | $219,558118 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $752 | $164,28736 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,024 | $162,44918 claims |
| AbbVieVraylar | $665 | $145,15096 claims |
| Alkermes, Inc.Aristada | $1,377 | $22,68214 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $429 | $17,45412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $40 | $11,93228 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $1,037213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Raleigh
- Michele CerraRaleigh$332K
- Carrie PettitRaleigh$298K
- Jennifer GibbsRaleigh$216K
- Holly StarnesRaleigh$69K
- Harry LayRaleigh$63K
- Lauren HendricksRaleigh$17K
- Margaretann HouseRaleigh$16K
- Gretchen ReichmannRaleigh$13K
- Leslie ByrneFayetteville$482K
- Anne LakeArchdale$306K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.